We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · December 26, 2019

Long-Term Efficacy of Every-2-Week Dosing vs Recommended Dosing of Ixekizumab in Patients Who Had Static Physician's Global Assessment >1 at Week 12

The British Journal of Dermatology

 

Additional Info

The British Journal of Dermatology
An Indirect Comparison of Long-Term Efficacy of Every-2-Week Dosing vs Recommended Dosing of Ixekizumab in Patients Who Had Static Physician's Global Assessment >1 at Week 12
Br J Dermatol 2019 Sep 23;[EPub Ahead of Print], K Papp, C Maari, A Cauthen, M Gooderham, L Spelman, K Yamanaka, P Polzer, L Zhang, O Osuntokun, M Augustin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading